Postech Academy-industry Foundation

Interoligo Corporation

Posco

Ulsan National Institute of Science and Technology

Korea Food & Drug Administration

Unist, Inc.

Jong Hun Im

Jung Hwan Lee

Jong In Kim

Sung Ho Ryu

Sung Key Jang

Young Chan Chae

Ki Seok Kim

Hyungu Kang

Youndong Kim

Hye Jung Lee

Mi-Jin Kwon

Soon Hag Kim

Sun Hak Lee

Eun Jung Jang

Jin Woo Kim

Pann-Ghill Suh

Eun Ju Oh

Won Jun Kang

Jong Ook Lee

Yu Jin Lee

Min Jeong Choi

Il Shin Kim

Il Ung Oh

Youngdong Kim

Youn Dong Kim

Ii Shin Kim

Seungmin Han

Jiyoun Lee

Sehoon Park

Ara Koh

Na-Oh Yunn

A composition for imaging a tumorous disease region includes a fluorescence- or radioactive isotope-labeled ERBB2 aptamer, wherein the ERBB2 aptamer labeled with a radioactive isotope or a fluorescent dye is used to image the tumorous disease region in vivo. The composition may include a labeled hybridized aptamer comprising an aptamer represented as formula 1 hybridized with a labeled-ODN represented as formula 2.

Biomolecule imaging method using aptamer

A cancer targeted therapeutic agent includes a drug-linker-AS1411 structure. The drug may be selected from monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), cytarabine, gemcitabine, maytansine, DM1, DM4, calicheamicin and a derivative thereof, doxorubicin, duocarmycin and a derivative thereof, pyrrolobenzodiazepine (PBD), SN-38, a-amanitin, or a tubulysin analog.

Aptamer-drug conjugate and use thereof

The present disclosure relates to a DNA aptamer which specifically binds to an insulin receptor, and a composition for treating diabetes and a composition for diagnosing diabetes which contain the same as an active ingredient, and the aptamer is characterized by being able to treat and diagnose diabetes more effectively than side effects caused by insulin such as increased incidence of cancer and atherosclerosis by having a different binding mechanism from existing insulin.

Aptamer against insulin receptor and pharmaceutical compostion containing the same

This disclosure relates to DNA aptamer specifically binding to periostin, which is cancer-related protein, a composition for inhibiting cancer and/or cancer metastasis and/or a composition for diagnosis of cancer and/or cancer metastasis, comprising the same as an active ingredient, wherein the aptamer has different binding mechanism from the existing antibodies, and thus, may inhibit and diagnose cancer/cancer metastasis more effectively.

Aptamer for periostin and anti-cancer composition including same

Disclosed are a DNA aptamer specifically binding to the Her2 (ERBB2) receptor involved in the onset of breast cancer, a composition for the suppression of cancer metastasis comprising the same as an active ingredient, and a composition for the diagnosis of cancer comprising the same as an active ingredient. Due to its binding mechanism being different from that of the conventional antibody, the aptamer can be effectively used for suppressing cancer metastasis and diagnosing cancer.

Aptamer which selectively binds to ERBB2 receptor and uses thereof

Improved G-rich oligonucleotide (GRO) aptamers specific to nucleolin, a method of preparing the aptamers, and a use of the aptamers for diagnosing and/or treating a nucleolin-associated disease, are provided.

Method of diagnosing cancer using a nucleolin specific aptamer

Method of treating hyperproliferation of cells using a nucleolin specific aptamer

Growing community of inventors

Seoul, South Korea

Jong Hun Im